DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Letairis (Ambrisentan) - Published Studies

 
 



Letairis Related Published Studies

Well-designed clinical trials related to Letairis (Ambrisentan)

Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. [2010.02]

Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. [2010]

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. [2009.11.17]

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. [2008.12]

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. [2008.06.10]

Ambrisentan therapy for pulmonary arterial hypertension. [2005.08.02]

Well-designed clinical trials possibly related to Letairis (Ambrisentan)

Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. [2012]

[Treatment of pulmonary fibrosis : New substances and new interventions.] [2011.11.19]

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. [2009]

[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.] [2005.06]

Other research related to Letairis (Ambrisentan)

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. [2012]

Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. [2011.09]

Ambrisentan. [2011.08.01]

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. [2011.07.15]

Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. [2011.05.01]

Pharmacokinetic evaluation of ambrisentan. [2011.03]

Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. [2011.01]

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. [2011]

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. [2010.10]

Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. [2010]

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. [2010]

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. [2009.08]

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. [2009.06]

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. [2009.05]

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. [2009.01]

Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer. [2009]

Ambrisentan and its role in the management of pulmonary arterial hypertension. [2008.12]

Role of ambrisentan in the management of pulmonary hypertension. [2008.11]

Ambrisentan for the management of pulmonary arterial hypertension. [2008.05]

Raltegravir. [2008]

A review of pulmonary arterial hypertension: role of ambrisentan. [2007]

Ambrisentan, a non-peptide endothelin receptor antagonist. [2006.03]

Other possibly related research studies

Endothelin receptor antagonism : role in the treatment of pulmonary arterial hypertension related to scleroderma. [2008]

[Systemic sclerosis] [2008.05]

Management of pulmonary arterial hypertension associated with congenital heart disease. [2007]

[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008] [2008.04]

Endothelin receptor antagonists in pulmonary arterial hypertension. [2008.02]

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? [2008.03]

Expert opinion on available options treating pulmonary arterial hypertension. [2007.10]

Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. [2007.10]

Gateways to clinical trials. [2007.04]

EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils. [2007.07.09]

Gateways to clinical trials. [2007.03]

Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. [2007.03]

Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition? [2006.12]

[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists] [2006.12.08]

Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. [2006.09]

Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. [2005.12]

Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. [2006.06]

Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. [2006.06]

Gateways to clinical trials. [2006.01]

Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelin A receptor blockade after orthotopic liver transplantation in pigs. [2006.01]

Gateways to clinical trials. [2005.10]

Drug treatment of pulmonary arterial hypertension: current and future agents. [2005]

[Treatment algorithm for pulmonary arterial hypertension.] [2005.06]

Gateways to clinical trials. [2004.10]

Endothelin receptor antagonists in pulmonary arterial hypertension. [2004.06.16]

Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis. [2004.06]

Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function. [2002.08]

[Specific drugs for the treatment of pulmonary arterial hypertension - current status] [2008.10]

Pulmonary arterial hypertension: on the way to a manageable disease. [2008.09]

Gateways to clinical trials. [2008.03]

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. [2008]

[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment] [2008.08]

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? [2008.08]

Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. [2008]

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. [2009.06]

Pulmonary arterial hypertension in children: a medical update. [2009.01]

Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis. [2010.04.28]

Pharmacotherapeutic management of pulmonary arterial hypertension. [2010.05]

[Endothelin receptor antagonists - their role in pulmonary medicine] [2009.12]

Therapeutic methods used in patients with Eisenmenger syndrome. [2009]

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. [2009.09.21]

Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. [2009.12]

Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. [2009]

Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. [2009.06]

Endothelin receptor antagonists - their role in pulmonary medicine. [2011.10]

[Treatment of idiopathic pulmonary arterial hypertension]. [2011.07.01]

Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. [2011.06]

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. [2011.07]

Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. [2011.03]

Endothelin receptor antagonists as disease modifiers in systemic sclerosis. [2011.02]

Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. [2010.12.01]

Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. [2011.03]

Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis. [2010.05]

Pulmonary arterial hypertension in connective tissue diseases. [2010.03]

Non-congenital heart disease associated pediatric pulmonary arterial hypertension. [2009.12.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012